E. Johansson

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

A. Svedbom, S. Hartz, E. Johansson, 2018, Journal of medical economics.

Cost-Effectiveness Analysis of Ixekizumab vs. Secukinumab in Sequential Biologic Treatment of Psoriasis in the UK

A. Svedbom, S. Hartz, E. Johansson, 2016 .

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

M. Belger, E. Johansson, S. Wilhelm, 2022, The Journal of Headache and Pain.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.

L. Rumbach, A. Gustavsson, K. Karampampa, 2012, Multiple sclerosis.

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

T. Dilla, A. Svedbom, M. Núñez, 2018, ClinicoEconomics and outcomes research : CEOR.